Treatment.Com International Inc. (TRUE.CN)
CAD 0.42
(5.06%)
CAD 0.42
(5.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -273.39 Thousand CAD | -148.49% |
| 2022 | 563.78 Thousand CAD | 161.5% |
| 2021 | -916.75 Thousand CAD | -193.23% |
| 2020 | -312.64 Thousand CAD | 39.34% |
| 2019 | -515.39 Thousand CAD | -1947.0% |
| 2018 | -25.17 Thousand CAD | -128.45% |
| 2017 | -11.02 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -844.5 Thousand CAD | 54.19% |
| 2024 Q1 | -1.84 Million CAD | -574.31% |
| 2023 Q4 | -273.39 Thousand CAD | 5.14% |
| 2023 Q3 | -288.22 Thousand CAD | -142.04% |
| 2023 Q2 | 685.54 Thousand CAD | 9.42% |
| 2023 Q1 | 626.53 Thousand CAD | 11.13% |
| 2023 FY | -273.39 Thousand CAD | -148.49% |
| 2022 Q4 | 563.78 Thousand CAD | 24.58% |
| 2022 Q2 | 323.49 Thousand CAD | 578.5% |
| 2022 Q1 | -67.6 Thousand CAD | 92.63% |
| 2022 FY | 563.78 Thousand CAD | 161.5% |
| 2022 Q3 | 452.56 Thousand CAD | 39.9% |
| 2021 Q1 | -1.54 Million CAD | -393.72% |
| 2021 FY | -916.75 Thousand CAD | -193.23% |
| 2021 Q4 | -916.75 Thousand CAD | 56.01% |
| 2021 Q3 | -2.08 Million CAD | 50.9% |
| 2021 Q2 | -4.24 Million CAD | -174.98% |
| 2020 Q4 | -312.64 Thousand CAD | 67.64% |
| 2020 Q1 | 515.39 Thousand CAD | 200.0% |
| 2020 Q3 | -966.21 Thousand CAD | 0.0% |
| 2020 FY | -312.64 Thousand CAD | 39.34% |
| 2019 FY | -515.39 Thousand CAD | -1947.0% |
| 2019 Q4 | -515.39 Thousand CAD | 0.0% |
| 2018 FY | -25.17 Thousand CAD | -128.45% |
| 2017 FY | -11.02 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AI/ML Innovations Inc. | -3732.00 CAD | -7225.67% |
| Diagnamed Holdings Corp. | -606.96 Thousand CAD | 54.957% |
| Pangenomic Health Inc. | 952.18 Thousand CAD | 128.712% |
| nDatalyze Corp. | -794.1 Thousand CAD | 65.572% |
| Unidoc Health Corp. | -324.03 Thousand CAD | 15.627% |